Literature DB >> 12649307

(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters.

Richard B Rothman1, Robert D Clark, John S Partilla, Michael H Baumann.   

Abstract

(+/-)-Fenfluramine is an amphetamine analog that was once widely prescribed as an appetite suppressant. Although (+/-)-fenfluramine is no longer clinically available, the mechanisms underlying its anorectic properties are still of interest. Upon peripheral administration, stereoisomers of (+/-)-fenfluramine are N-deethylated to form the metabolites, (+)- and (-)-norfenfluramine. It is well accepted that isomers of (+/-)-fenfluramine and (+/-)-norfenfluramine interact with 5-hydroxytryptamine (serotonin, 5-HT) transporters to release 5-HT from neurons. However, the effects of these drugs on other monoamine transporters are not well characterized. In this study, we examined the interaction of stereoisomers of (+/-)-fenfluramine and (+/-)-norfenfluramine with transporters for 5-HT, norepinephrine (NE), and dopamine (DA). Results from in vitro assays confirmed these drugs are potent substrates for 5-HT transporters: (+)-fenfluramine, (-)-fenfluramine, (+)-norfenfluramine, and (-)-norfenfluramine released [3H]5-HT from synaptosomes with EC50 values of 52, 147, 59, and 287 nM, respectively. Importantly, (+)-fenfluramine and (+)-norfenfluramine released [3H]NE with EC50 values of 302 and 73 nM. Results from in vivo microdialysis experiments showed that intravenous injection of (+)-norfenfluramine elevates extracellular levels of 5-HT, NE, and DA in rat frontal cortex. The effects of (+)-norfenfluramine on NE and DA were antagonized by pretreatment with the NE uptake blocker nisoxetine. In summary, administration of fenfluramines can increase synaptic levels of 5-HT, NE, and DA in the cortex, and (+)-norfenfluramine likely contributes to these effects. Release of NE and DA evoked by (+)-norfenfluramine is at least partly mediated via NE transporters. Our results emphasize the potential involvement of noradrenergic mechanisms in the actions of fenfluramines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649307     DOI: 10.1124/jpet.103.049684

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

Review 1.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

2.  A serotonin and melanocortin circuit mediates D-fenfluramine anorexia.

Authors:  Yong Xu; Juli E Jones; Danielle A Lauzon; Jason G Anderson; Nina Balthasar; Lora K Heisler; Andrew R Zinn; Bradford B Lowell; Joel K Elmquist
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

Review 3.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

5.  Identification of Serotonergic Neuronal Modules that Affect Aggressive Behavior.

Authors:  Vera Niederkofler; Tedi E Asher; Benjamin W Okaty; Benjamin D Rood; Ankita Narayan; Lara S Hwa; Sheryl G Beck; Klaus A Miczek; Susan M Dymecki
Journal:  Cell Rep       Date:  2016-11-15       Impact factor: 9.423

Review 6.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

7.  N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Authors:  Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2017-05-22       Impact factor: 7.853

8.  Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues.

Authors:  J S Bonano; M L Banks; R Kolanos; F Sakloth; M L Barnier; R A Glennon; N V Cozzi; J S Partilla; M H Baumann; S S Negus
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

Review 9.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

Review 10.  Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.